For how we live.
The TRACK trial was stopped early for futility. The blood thinner failed to reduce a composite of cardiovascular events, while major bleeding rose by half. Bayer, which makes the drug, was a listed collaborator.
For most adults who bruise more than they used to, the cause is thinner skin from ageing, sun or steroids, plus the aspirin and anticoagulants many older people take. A few patterns point elsewhere.
Self-testing and self-managing warfarin cut clot events by roughly 40%, and self-management also lowered deaths — one of the few at-home tests with randomised evidence of real benefit.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
Guidelines have hedged on anticoagulation for people with one stroke risk factor. SINGLE-AF randomised 1,803 patients in South Korea, and the events it counted were very few in both arms.
The STABLED trial randomized 331 atrial fibrillation patients with a recent stroke to ablation plus anticoagulation or anticoagulation alone. The two groups ended up nearly identical.